dostęp otwarty
Advances in the management of gastrointestinal stromal tumors (GISTs)
, 1
Afiliacje- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
dostęp otwarty
Streszczenie
Gastrointestinal stromal tumors are rare neoplasms developing from cells of Cajal in the gastrointestinal tract. The mainstay of such tumors treatment is surgery, whenever possible. The therapeutic management of inoperable and metastatic disease is based on tyrosine kinase inhibitors and imatinib is the main drug recommended for first line treatment. The introduction of imatinib and other inhibitors improved survival outcomes for this disease, but due to primary and secondary resistance there is still the urgent need for new medications. This paper presents the progress in the systemic therapy of GISTs based on the latest scientific data. The newly developed agents (ripretinib, avapritinib) meet the need to treat patients after the failure of previously available therapies and those with PDGFRA mutation D842V associated with resistance to imatinib.
Streszczenie
Gastrointestinal stromal tumors are rare neoplasms developing from cells of Cajal in the gastrointestinal tract. The mainstay of such tumors treatment is surgery, whenever possible. The therapeutic management of inoperable and metastatic disease is based on tyrosine kinase inhibitors and imatinib is the main drug recommended for first line treatment. The introduction of imatinib and other inhibitors improved survival outcomes for this disease, but due to primary and secondary resistance there is still the urgent need for new medications. This paper presents the progress in the systemic therapy of GISTs based on the latest scientific data. The newly developed agents (ripretinib, avapritinib) meet the need to treat patients after the failure of previously available therapies and those with PDGFRA mutation D842V associated with resistance to imatinib.
Słowa kluczowe
gastrointestinal stromal tumor; GIST; tyrosine kinase inhibitor; imatinib; regorafenib; sunitinib; sorafenib; avapritinib; repritinib; BLU-285; DCC-2618
Informacje o artykuleTytuł
Advances in the management of gastrointestinal stromal tumors (GISTs)
Czasopismo
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory
Numer
Strony
385-392
Opublikowany online
2020-12-03
Wyświetlenia strony
532
Wyświetlenia/pobrania artykułu
128
Rekord bibliograficzny
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2020;5(6):385-392.
Słowa kluczowe
gastrointestinal stromal tumor
GIST
tyrosine kinase inhibitor
imatinib
regorafenib
sunitinib
sorafenib
avapritinib
repritinib
BLU-285
DCC-2618
Autorzy
Monika Dudzisz-Śledź
Piotr Rutkowski
Referencje (39)- Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016; 40: 39–46.
- Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438(1): 1–12.
- Ahmed M. Recent advances in the management of gastrointestinal stromal tumor. World J Clin Cases. 2020; 8(15): 3142–3155.
- Rutkowski P, Szumera-Ciećkiewicz A. Gastrointestinal stromal tumours (GIST) — 2018. Oncol Clin Pract. 2019; 14(6): 399–407.
- Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001; 54(2): 96–102.
- Casali PG, Abecassis N, Aro HT, et al. ESMO Guidelines Committee and EURACAN, ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv68–iv78.
- Rutkowski P, Hompes D. Combined Therapy of Gastrointestinal Stromal Tumors. Surg Oncol Clin N Am. 2016; 25(4): 735–759.
- Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12): 1265–1272.
- Joensuu H, Eriksson M, Hall KS, et al. Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up. Journal of Clinical Oncology. 2020; 38(15_suppl): 11503–11503.
- Rutkowski P, Ziętek M, Cybulska-Stopa B, et al. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice. Eur J Surg Oncol. 2020 [Epub ahead of print].
- Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012; 19(4): 1074–1080.
- Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013; 20(9): 2937–2943.
- Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7): 472–480.
- Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4): 620–625.
- Rutkowski P, Andrzejuk J, Bylina E, et al. What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib? Med Oncol. 2013; 30(4): 765.
- Brzozowska M, Wierzba W, Szafraniec-Buryło S, et al. Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland. Med Sci Monit. 2019; 25: 3846–3853.
- Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544): 1329–1338.
- Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015; 121(9): 1405–1413.
- Sutent (sunitinib) SmPC. https://www.ema.europa.eu/en/documents/product-information/sutent-epar-product-information_en.pdf.
- Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer. 2013; 49(5): 1027–1031.
- Rutkowski P, Jagielska B, Andrzejuk J, et al. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). Contemp Oncol (Pozn). 2017; 21(4): 285–289.
- Demetri G, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 295–302.
- Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013; 14(12): 1175–1182.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Gastrointestinal Stromal Tumors (GISTs), version 1.2021. 10.2020. 2021.
- https://www.clinicaltrials.gov/ct2/results?cond=GIST&term=&cntry=&state=&city=&dist=.
- Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014; 40(4): 412–419.
- Du CY, Zhou Ye, Song C, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer. 2014; 50(10): 1772–1778.
- Tielen R, Verhoef C, van Coevorden F, et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol. 2012; 10(2): 111–155.
- AYVAKYT (avapritinib) SMPC. https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf.
- AYVAKYT (avapritinib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf.
- Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by mutations. Sci Transl Med. 2017; 9(414).
- Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020; 21(7): 935–946.
- Jones RL, Serrano C, von Me, et al. Long-term efficacy, tolerability and overall survival in patients with unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumor treated with avapritinib: NAVIGATOR phase 1 trial update. Ann Oncol. 2020; 31(Suppl 4): abstract 1621MO.
- https://clinicaltrials.gov/ct2/show/NCT03465722.
- https://www.prnewswire.com/news-releases/blueprint-medicines-announces-top-line-results-from-phase-3-voyager-trial-of-avapritinib-versus-regorafenib-in-patients-with-advanced-gastrointestinal-stromal-tumor-301048058.html.
- QINLOCK (ripretinib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf.
- Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 2019; 35(5): 738–751.e9.
- Blay JY, Serrano C, Heinrich M, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(7): 923–934.
- George S, Heinrich M, Chi P, et al. Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Annals of Oncology. 2018; 29: viii576–viii577.
